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O B J E C T I V E S This study sought to evaluate the relationship between platelet reactivity and
atherosclerotic burden in patients undergoing percutaneous coronary intervention (PCI) with pre-
intervention volumetric intravascular ultrasound (IVUS) imaging.
B A C KG ROUND Atherosclerosis progresses by the pathologic sequence of subclinical plaque
rupture, thrombosis, and healing. In this setting, increased platelet reactivity may lead to more extensive
arterial thrombosis at the time of plaque rupture, leading to a more rapid progression of the disease.
Alternatively, abnormal vessel wall biology with advanced atherosclerosis is known to enhance platelet
reactivity. Therefore, it is possible that by either mechanism, increased platelet reactivity may be
associated with greater atherosclerotic burden.
METHOD S This study included patients who underwent PCI with pre-intervention IVUS imaging
and platelet reactivity functional assay (P2Y12 reaction units) performed 16 h after PCI, after the
stabilization of clopidogrel therapy (administered before PCI). Platelet reactivity 230 P2Y12 reaction
units deﬁned high on-treatment platelet reactivity (HPR).
R E S U L T S Among 335 patients (mean age 65.0 years, 71% men), there were 109 patients with HPR
(32.5%) and 226 without HPR (67.5%), with HPR being associated with diabetes and chronic renal
insufﬁciency. By IVUS analysis, patients with HPR had signiﬁcantly greater target lesion calcium lengths,
calcium arcs, and calcium indexes. Furthermore, patients with HPR tended to have longer lesions and
greater volumetric dimensions, indicating higher plaque volume, larger total vessel volume, and also
greater luminal volume, despite similar plaque burden. By multivariate analysis controlling for baseline
clinical variables, HPR was the single consistent predictor of all IVUS parameters examined, including
plaque volume, calcium length, and calcium arc.
CONC L U S I O N S Increased platelet reactivity on clopidogrel treatment, deﬁned as 230 P2Y12
reaction units, is associated with greater coronary artery atherosclerotic disease burden and plaque
calciﬁcation. (J Am Coll Cardiol Img 2012;5:540–9) © 2012 by the American College of Cardiology
Foundation
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541nhanced platelet reactivity plays a pivotal role
in arterial ischemic events, acute coronary
syndromes, and complications of percutane-
ous coronary intervention (PCI) (1). In ad-
dition, the complex interactions among platelets,
inflammatory cells, vascular cells, and chemokines
also play a major role in atherosclerotic plaque and
neointimal formation (2,3). Putative mechanisms
whereby platelets may promote atherosclerosis in-
clude: 1) releasing chemokines and their precursors,
which trigger the atherogenic recruitment of vascu-
lar cells or modulate processes such as angiogenesis
or lipoprotein metabolism; 2) inducing chemokine
secretion by endothelial and other vascular cells;
and 3) binding and presenting vascular cell–derived
chemokines to trigger arrest of circulating mono-
nuclear cells (2,4–8). Huo et al. (9) showed that the
injection of activated platelets exacerbated athero-
sclerotic lesion formation, a process involving plate-
let surface receptors that facilitate mononuclear cell
recruitment. The deposition of the most abundant
platelet chemokine, platelet factor-4, has been cor-
related with lesion severity and symptomatic ath-
erosclerosis, suggesting that persistent platelet acti-
vation may contribute to the evolution of vascular
lesions and supporting the rationale for long-term
antiplatelet therapy in patients at risk for athero-
sclerosis (10). These observations not only extend
the current view of platelets as being responsible for
adhesion to the endothelium and propagation of
endovascular thrombosis but also suggest that acti-
vated platelets play an important role in promoting
the atherosclerotic process itself, in particular the
stages relating to acute coronary syndromes. Fur-
thermore, it is also well described that alterations in
the vascular wall or situations inducing high shear
stress may lead to secondary platelet activation
(11,12). Therefore, as either a primary cause or a
secondary consequence, there is a strong rationale
to expect that platelet activation may be associated
with atherosclerotic plaque burden.
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ber 8, 2011, accepted December 5, 2011.Antiplatelet therapy is a cornerstone of cardio-
vascular disease management and secondary pre-
vention (13). Significant reductions in ischemic
complications in a wide range of patients with
coronary artery disease have been demonstrated in
major randomized controlled trials by the use of
dual-antiplatelet therapy with a thienopyridine plus
aspirin (14,15). However, clopidogrel nonrespon-
siveness (characterized as high on-treatment plate-
let reactivity [HPR]) (16) has been recognized to
correlate with adverse events after acute coronary
syndromes and PCI (17–24). Because most patients
with known coronary artery disease are receiving
long-term antiplatelet therapy, assessment of plate-
let reactivity and ascertainment of HPR status are
relevant to clinical practice and patient outcomes.
Importantly, a recent meta-analysis demonstrated
that HPR is associated with long-term cardiovas-
cular events after PCI, including death, myocardial
infarction, and stent thrombosis (24). Although it is
widely assumed that this is due to increased throm-
botic events, a preliminary study recently
reported that HPR may be associated with
increased coronary artery atherosclerotic
burden as assessed by cine angiography
(25). In the present study, we sought to
extend these findings and determine if
HPR, as an indicator of high residual
platelet reactivity in patients receiving
clopidogrel, correlates with more extensive
atherosclerotic disease as determined by
volumetric intravascular ultrasound
(IVUS) imaging, the gold-standard imag-
ing modality for the assessment of atherosclerotic
burden and calcification.
M E T H O D S
Patient population, PCI, and IVUS image acquisition.
We analyzed 335 consecutive patients who under-
went PCI with pre-intervention IVUS imaging and
who had platelet function testing performed on the
day after PCI. Only a single culprit target lesion and
associated target vessel per patient were included in
this study. IVUS of other vessels was not clinically
indicated and was not performed. Key enrollment
criteria were as follows: guideline-appropriate re-
quirement for PCI, typically based on severe dis-
ease, positive stress test results, or presentation with
unstable coronary syndromes; age 18 years; and
signed informed consent. Exclusion criteria were as
follows: presentation with ST-segment elevation
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542prior heart transplantation; active autoimmune dis-
ease; illicit drug use; human immunodeficiency virus
infection; prior malignancy with mediastinal irradia-
tion, bone marrow transplantation, or high-dose che-
motherapy; and adult congenital heart disease.
PCI procedures were performed according to
current standard guidelines, and the type of stent
implanted and the use of pharmacological agents
were at the discretion of the operator. The decision
to perform IVUS was also at the discretion of the
operator and was made entirely independently of
this study, with 80% of all IVUS images acquired
before this study was conceived. If the patient had
no prior exposure to clopidogrel (n  132), a dose
f 600 mg was administered no later than 2 h before
CI; patients already treated with clopidogrel be-
ore hospitalization received a loading dose of 300
g before PCI (n  203). After PCI, all patients
eceived aspirin, clopidogrel, and a statin. For the
urposes of this analysis, patients with anemia (hemo-
lobin 10.5 g/dl), those with thrombocytopenia
platelet count 125,000/ml), and those receiving
Table 1. Baseline Patient Characteristics in the Overall Study Po
Overall
(n  3
Age (yrs) 65.0 (58.0
Men 71.0 (238
Body surface area (m2) 1.93 (1.79
Platelet count (1,000/l) 196 (164
Prior MI 21.5 (72/
Stroke/TIA 6.6 (22/
Congestive heart failure* 7.5 (25/
Hypertension 77.9 (261
Hyperlipidemia 80.5 (269
Diabetes mellitus† 31.6 (106
Chronic renal insufﬁciency‡ 9.3 (31/
Current smoking 9.9 (33/
Additional medication use
Beta-blockers 66.9 (220
Statins 70.9 (234
ACE inhibitors 34.8 (115
Anatomical location of target lesion
Left main 2.1 (7/3
LAD 44.4 (148
LAD branch (diagonal) 3.6 (12/
LCx 14.1 (47/
LCx branch (ramus intermedius, OM, LPL, LPDA) 8.1 (27/
RCA 24.6 (82/
RCA branch (AV continuation, RPDA, RPL) 3.0 (10/
Values are median (interquartile range) or % (n/N). *New York Heart Associati
60 ml/min/1.72 m2.
ACE  angiotensin-converting enzyme; AV  atrioventricular; HPR  high on-
left circumﬂex coronary artery; LPDA  left posterior descending artery; LPL 
coronary artery; RPDA  right posterior descending artery; RPL  right posterolatelycoprotein IIb/IIIa inhibitors during or after
CI were excluded because of the possibility of
nterference with platelet assay measurements.
Platelet reactivity testing. The VerifyNow point-of-
are assay (Accumetrics, San Diego, California) was
sed to measure platelet reactivity. This test has
een previously described in detail (26); it is a
urbidimetry-based optical detection device that
easures platelet-induced aggregation in a system
ontaining fibrinogen-coated beads. The instru-
ent measures changes in light transmission and
hus the rate of aggregation in whole blood. In the
artridge used for this assay, there is a channel in
hich inhibition of the P2Y12 receptor is measured;
his channel contains adenosine diphosphate as a
latelet agonist and prostaglandin E1 as a suppressor
of intracellular free calcium levels, to reduce the
nonspecific contribution of adenosine diphosphate
binding to P2Y12 receptors. Venous blood samples
anticoagulated with sodium citrate 0.109 mol/l (ratio
9:1) were tested from each patient 16 to 24 h after
PCI (as part of the clinically determined morning
ation and in the Groups With and Without HPR
up HPR
(n  109)
No HPR
(n  226) p Value
.0) 66.0 (58.4–74.0) 65.0 (57.8–72.0) 0.28
) 61.5 (67/109) 75.7 (171/226) 0.01
3) 1.95 (1.80–2.16) 1.93 (1.79–2.12) 0.70
2) 189 (158–220) 198 (167–236) 0.037
18.3 (20/109) 23.0 (52/226) 0.40
3.7 (4/109) 8.0 (18/226) 0.16
8.3 (9/109) 7.1 (16/226) 0.67
) 79.8 (87/109) 77.0 (174/226) 0.67
) 81.5 (88/108) 80.1 (181/226) 0.88
) 45.9 (50/109) 24.8 (56/226) 0.0002
14.7 (16/109) 6.6 (15/226) 0.026
8.3 (9/109) 10.6 (24/226) 0.56
) 67.3 (72/107) 66.7 (148/222) 1.00
) 66.7 (72/108) 73.0 (162/222) 0.25
) 32.4 (35/108) 36.0 (80/222) 0.54
3.7 (4/108) 1.3 (3/225) 0.22
) 47.2 (51/108) 43.1 (97/225) 0.48
3.7 (4/108) 3.6 (8/225) 1.00
9.3 (10/108) 16.4 (37/225) 0.093
9.3 (10/108) 7.6 (17/225) 0.67
23.1 (25/108) 25.3 (57/225) 0.69
3.7 (4/108) 2.7 (6/225) 0.73
nctional class III or IV. †Requiring medical therapy. ‡Glomerular ﬁltration rate
ment platelet reactivity; LAD  left anterior descending coronary artery, LCx 
osterolateral; MI  myocardial infarction; OM  obtuse marginal; RCA  rightpul
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543blood tests) but before the next dose of clopidogrel.
Results are expressed as P2Y12 reaction units. Platelet
eactivity  230 P2Y12 reaction units was used to
define patients with HPR clopidogrel resistance (27).
IVUS image analysis. Target lesion IVUS imaging
studies were performed after intracoronary admin-
istration of 200 g nitroglycerin using a commer-
cially available IVUS system (Atlantis SR Pro,
40-MHz catheter, Boston Scientific Corporation,
Natick, Massachusetts; Eagle Eye, 20-MHz cath-
eter, or Revolution 45-MHz catheter, Volcano
Corporation, Rancho Cordova, California) and be-
fore any coronary intervention. The IVUS catheter
was advanced distal to the stenosis, and imaging
was performed with retrograde pullback to the
aorto-ostial junction at an automatic pullback speed
of 0.5 mm/s. All analyses were performed offline
without knowledge of the platelet assay results
using planimetry software (Indec Systems Inc.,
Mountain View, California). The minimal luminal
cross-sectional area (CSA) site was the image slice
with the smallest luminal CSA. The reference sites
were the most normal appearing cross-sections
within 5 mm proximal and distal to the stenosis, but
before any side branch, and were used to calculate a
mean reference. For each patient, the lesion with
the smallest luminal CSA was chosen for analysis.
The lesion itself was defined as the segment be-
tween the proximal and distal reference sites whose
length (in millimeters) was calculated using the
pullback duration and pullback speed. Quantitative
analysis included measurement of the external elas-
tic membrane (EEM) and luminal CSA every 1 mm
within the length of the lesion. Plaque and media
CSA was calculated as EEM minus luminal CSA.
Once a complete set of CSA measurements were
obtained, EEM, plaque plus media, and luminal
volumes were calculated using Simpson’s rule.
Plaque burden was calculated as plaque and media
divided by EEM volume or CSA. A remodeling
index was calculated as the lesion divided by the
mean reference EEM CSA. Calcium was identified
as an echo signal brighter than the adventitia with
acoustic shadowing. The maximal arc of calcium (in
degrees) within the lesion was measured with the
electronic protractor centered on the lumen. Cal-
cium length (in millimeters) within the lesion was
measured as the length of the lesion in which there
was IVUS-detectable calcium. Calcium index was
calculated as: total calcium length/lesion length 
maximal calcium arc/360°.
Clinical patient follow-up. All patients had follow-up
ompleted out to 12 months or to fatal events.ollow-up data were collected from patients using
cripted telephone interviews and simultaneous
lectronic medical record review. If telephone con-
act was not established, a mailed questionnaire was
sed. Major adverse cardiovascular events (death,
yocardial infarction, or target lesion revasculariza-
ion) were adjudicated by an independent committee.
he Social Security Death Index was used to obtain
he vital status of patients. These methods are the
tandard operation of the Columbia University Med-
cal Center PCI outcomes database registry, which
ncludes data collection and follow-up under institu-
ional review board approval.
Figure 1. Illustrative Volumetric Intravascular Ultrasound Image
Patients With and Without HPR
(Top) An example of a patient with high on-treatment platelet reac
(HPR). This long lesion (27.5 mm from proximal to distal reference s
tains diffuse calciﬁcation (note the acoustic shadows beyond region
ﬁcation), with a maximal calcium arc of 360° at the minimum lumin
(MLA) site. (Bottom) A patient without HPR. Although not intended
representative, the lesion length was shorter (11 mm from proxima
reference site) with noncalciﬁed plaque at the MLA site; the maxim
calcium (70°) was located at the proximal reference. Both lesions ha
areas at the lesion site of 3.0 mm2, considered to be highly hemos From
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544Statistical analyses. Continuous variables are ex-
ressed as mean  SD or as median (interquartile
ange) as indicated and were compared using Stu-
ent t tests or Wilcoxon rank sum tests if applica-
ble. Discrete variables and clinical outcomes are
expressed as frequencies and percents and were
compared using chi-square tests, unless the obser-
vations in any cell were 5, in which case Fisher
exact tests were used. All statistical tests were
2-sided, with a significance level of 0.05. Multi-
variate linear regression analysis was used to assess
the relationship between HPR and IVUS measure-
ments while controlling for the following baseline
factors: age, sex, diabetes, and chronic renal failure.
A stepwise selection algorithm with entry and stay
criteria of 0.1 and 0.1 was used to identify multi-
variate predictors. Adjusted mean values for IVUS
measurements were calculated using least squares
mean estimation from a linear regression model. All
statistical analyses were performed using SAS ver-
sion 9.2 (SAS Institute Inc., Cary, North Carolina).
R E S U L T S
Among the 335 patients analyzed, there were 109
with HPR (32.5%) and 226 without HPR (67.5%).
Patient baseline characteristics are presented in
Table 2. Intravascular Ultrasound Measurements in the Overall
Platelet Reactivity Status
Overall Group
(n  335)
Reference site*
EEM CSA (mm2) 12.0 (9.3–15.2)
Luminal CSA (mm2) 6.5 (5.1–7.9)
Plaque burden 0.45 (0.38–0.52)
Minimum luminal area site
EEM CSA (mm2) 10.7 (8.5–13.6)
Luminal CSA (mm2) 3.0 (2.3–3.8)
Plaque and media CSA (mm2) 7.5 (5.5–10.0)
Plaque burden 0.71 (0.64–0.77)
Volumetric data
EEM volume (mm3) 100.9 (58.6–174.4)
Luminal volume (mm3) 38.5 (25.0–61.7)
Plaque and media volume (mm3) 58.6 (33.1–108.7)
Plaque burden 0.61 (0.55–0.66)
Lesion length (mm) 8.1 (5.5–13.1)
Calcium length (mm) 4.7 (1.7–8.8)
Maximal calcium arc (°) 110 (50–190)
Calcium index 0.17 (0.04–0.40)
Remodeling index 0.90 (0.79–1.02)
Values are median (interquartile range). *Calculated as the average of proxima
CSA  cross-sectional area; EEM  external elastic membrane; HPR  high on-treTable 1; HPR was associated with diabetes and
chronic renal insufficiency.
Volumetric IVUS analysis was performed in all
335 patients (Fig. 1, Table 2). There was no
difference in proximal or distal reference segments
in terms of plaque area or plaque burden. Plaque
burden at the minimal luminal site was similar
between the 2 groups. The HPR group had signif-
icantly greater calcification lengths, calcification
arcs, and calcium indexes. In addition, patients with
HPR tended to have longer lesions and greater
volumetric dimensions despite a similar plaque
burden. Similar results were obtained when only
patients receiving clopidogrel at the time of enroll-
ment were evaluated (Table 3).
Clinical events were rare (Table 4), and there was
no significant difference between patients with and
those without HPR. However, the present study
was not designed or powered to detect differences in
clinical outcomes.
After exploratory analyses to identify univariate
predictors, multivariate analysis was performed
against each of the IVUS-derived variables using
the following candidate predictors: HPR, age, sex,
diabetes, and chronic renal insufficiency. Table 5
indicates that HPR was the single consistent pre-
dictor of all IVUS parameters examined. Male sex
dy Population and by Groups According to
HPR
(n  109)
No HPR
(n  226) p Value
12.2 (9.8–15.0) 11.6 (9.1–15.4) 0.355
6.7 (5.1–8.0) 6.3 (5.1–7.9) 0.535
0.45 (0.39–0.53) 0.45 (0.37–0.52) 0.751
11.0 (8.5–14.0) 10.6 (8.4–13.5) 0.310
3.1 (2.4–4.0) 3.0 (2.2–3.7) 0.229
7.9 (5.6–10.0) 7.2 (5.4–10.0) 0.434
0.70 (0.64–0.77) 0.71 (0.65–0.77) 0.720
111.6 (66.6–177.5) 89.4 (57.4–169.0) 0.0526
44.4 (26.3–69.5) 36.3 (22.6–58.8) 0.0244
71.2 (36.7–111.2) 53.9 (32.9–103.6) 0.0726
0.61 (0.56–0.66) 0.61 (0.55–0.66) 0.869
8.8 (6.3–14.0) 7.6 (5.2–12.8) 0.0710
5.9 (2.6–10.5) 4.3 (1.4–7.4) 0.0096
130 (70–260) 90 (40–170) 0.0149
0.25 (0.07–0.45) 0.15 (0.03–0.38) 0.0250
0.92 (0.79–1.03) 0.90 (0.79–1.02) 0.834
distal reference sites.Stu
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545also correlated with EEM, luminal, and volumetric
plaque burden.
Table 6 depicts the IVUS parameters in the 2
groups after adjustment for age, sex, diabetes, and
chronic renal failure. Figure 2 indicates that the
trends observed in the univariate analyses between
the 2 study groups with respect to the IVUS
parameters were significantly strengthened after
adjustment for clinical variables.
D I S C U S S I O N
Our data demonstrate that platelet reactivity, as
assessed by HPR measurement, correlates with
diabetes and chronic renal insufficiency as well as
with increased calcification and atheroma burden as
assessed by IVUS in patients with coronary artery
disease requiring PCI. Compared with patients
without HPR, those with HPR exhibited increased
lesion lengths and plaque volumes despite also
having larger luminal volumes. Our analysis also
confirmed other previously reported observations,
including the fact that men have more plaque than
women (28). Importantly, ours is not the first study
to suggest that HPR is related to the extent of
coronary artery atherosclerotic disease. However,
the single prior study that we are aware of that
Table 3. Intravascular Ultrasound Measurements in Patients Alr
According to Platelet Reactivity Status
Overall Group
(n  203)
Reference site*
EEM CSA (mm2) 11.6 (9.3–15.0)
Luminal CSA (mm2) 6.3 (5.0–7.6)
Plaque burden 0.46 (0.38–0.53)
Minimum luminal area site
EEM CSA (mm2) 10.7 (8.7–13.9)
Luminal CSA (mm2) 3.0 (2.3–3.7)
Plaque and media CSA (mm2) 7.5 (5.5–10.3)
Plaque burden 0.71 (0.64–0.77)
Volumetric data
EEM volume (mm3) 92.3 (55.8–174.4)
Luminal volume (mm3) 37.4 (22.6–59.5)
Plaque and media volume (mm3) 56.0 (32.9–110.6)
Plaque burden 0.62 (0.55–0.66)
Lesion length (mm) 7.6 (5.3–13.0)
Calcium length (mm) 4.4 (1.3–8.7)
Maximal calcium arc (°) 100 (40–180)
Calcium index 0.15 (0.03–0.42)
Remodeling index 0.91 (0.79–1.03)
Values are median (interquartile range). *Calculated as the average of proxima
Abbreviations as in Table 2.suggested this relationship did not incorporate asensitive and objective imaging modality to deter-
mine atherosclerotic burden but rather relied en-
tirely on cine angiography with visual estimation of
disease severity (25). Therefore, our IVUS-based
findings add significantly to this former study,
extending our understanding of this relationship
and demonstrating that HPR is independently as-
sociated with sensitive measures of coronary ather-
oma burden and calcification.
Altered vessel wall characteristics may lead to
HPR. Our findings of increased calcification and
laque burden in patients with HPR raise impor-
ant biologic questions. Foremost, as a potential
echanistic explanation for our findings, intrinsic
hanges in the biology of the vessel wall may arise
y Receiving Clopidogrel at Enrollment by Groups
HPR
(n  58)
No HPR
(n  145) p Value
11.9 (10.2–14.5) 11.4 (9.1–15.4) 0.461
6.4 (5.3–7.6) 6.3 (5.0–7.6) 0.659
0.47 (0.39–0.53) 0.46 (0.38–0.52) 0.592
10.6 (8.5–13.9) 10.7 (8.8–13.9) 0.829
3.0 (2.5–3.8) 3.0 (2.2–3.7) 0.485
7.7 (5.5–9.9) 7.5 (5.5–10.3) 0.714
0.72 (0.63–0.77) 0.71 (0.65–0.78) 0.867
106.4 (67.8–200.3) 86.8 (51.8–161.2) 0.0962
42.2 (26.3–69.5) 34.7 (20.5–53.8) 0.0526
67.4 (37.4–127.5) 51.3 (30.9–102.9) 0.111
0.61 (0.56–0.67) 0.62 (0.55–0.66) 0.822
8.6 (6.4–14.5) 7.3 (4.9–12.5) 0.0652
7.0 (2.9–11.0) 3.8 (1.1–6.9) 0.0022
125 (70–270) 90 (33–165) 0.0055
0.28 (0.07–0.53) 0.11 (0.02–0.40) 0.0116
0.90 (0.78–1.04) 0.91 (0.80–1.02) 0.954
distal reference sites.
Table 4. Clinical Outcomes in the Overall Study Population and
With and Without HPR
Overall
Group
(n  335)
HPR
(n  109)
No H
(n 
MACEs 18.2 (61/335) 22.9 (25/109) 15.9 (3
Myocardial infarction 0.9 (3/335) 0.9 (1/109) 0.9 (2
TLR 17.9 (60/335) 22.9 (25/109) 15.5 (3
Death 0.6 (2/335) 0.0 (0/109) 0.9 (2
Values are % (n/N). No patient underwent coronary artery bypass graft surgery
HPR  high on-treatment platelet reactivity; MACE  major adverse cardioead
l andin the Groups
PR
226) p Value
6/226) 0.132
/226) 1.000
5/226) 0.128
/226) 1.000
.
vascular event (death,myocardial infarction, or TLR); TLR  target lesion revascularization.
IVUS  intravascular ultr
Abbreviations as in Table
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546because of diabetes, chronic renal insufficiency, or
plaque development (Tables 1, 5, and 6), which lead
to functional platelet abnormalities and increased
platelet reactivity (29). In support of this, both
diabetes and chronic renal insufficiency play a sig-
nificant role in arterial calcification and were pre-
liminarily reported to be associated with HPR in
another study (30). Furthermore, alterations in
arterial shear forces due to developing atheroscle-
rotic plaque may activate platelets (11), with addi-
tional human in vivo data corroborating the notion
that primary vascular disease processes lead to
platelet activation (12). Therefore, there is biologic
plausibility to suggest that our findings may be due
to atherosclerotic disease secondarily activating
platelets and leading to HPR.
Analysis Results for IVUS Variables and
Respective
edictor Coefﬁcient
Standard
Error p Value
1.58 0.83 0.0585
32.4 12.5 0.0101
1.76 0.70 0.0118
23.2 10.5 0.0284
31.6 10.9 0.0039
7.9 3.3 0.0161
7.4 3.4 0.0281
me/mm3
15.3 7.5 0.0432
24.2 7.8 0.0021
ded HPR, age, sex, diabetes, and chronic renal failure.
asound; other abbreviations as in Table 2.
for Intravascular Ultrasound Variables in Relation
After Adjustment for Age, Sex, Diabetes, and
HPR
(n  109)
No HPR
(n  226) p Value
11.0 0.7 9.4 0.5 0.0585
) 152.8 10.3 120.4 7.2 0.0101
7.2 0.6 5.4 0.4 0.0118
133.6 8.7 110.4 6.6 0.0284
) 49.2 2.7 41.3 2.0 0.0161
me (mm3) 84.4 6.2 69.0 4.7 0.04322.Increased platelet reactivitymay promote atherosclerosis.
As an alternative explanation, HPR may be a
marker of intrinsic platelet characteristics or func-
tionality that promote plaque formation and calci-
fication. Importantly, silent plaque rupture with
arterial thrombosis is a form of vascular wound
healing that leads to atherosclerotic progression
(31). Therefore, it is possible that increased platelet
reactivity may potentiate arterial thrombosis at the
time of plaque rupture, thereby driving inflamma-
tion and atherosclerotic progression. Moreover, in
addition to facilitating arterial thrombosis, several
studies have shown a key role for platelets in
mediating various nonthrombotic, inflammatory
pathways of plaque progression (32–36). On the
endothelial layer, platelet-derived chemokines, in
conjunction with increased expression of adhesion
molecules, promote the recruitment of circulating
monocytes that may migrate across the endothelial
lining and augment plaque progression. Further-
more, activated circulating platelets may induce
monocyte differentiation (32) or form platelet-
monocyte complexes that increase the adhesive and
migratory capacities of monocytes and promote the
additional recruitment of inflammatory cells
(37,38). Collectively, there are multiple possible
mechanisms whereby patients with high platelet
reactivity may develop more advanced atheroscle-
rotic and calcific arterial disease. Importantly, al-
though we measured platelet reactivity and ascer-
tained HPR in patients receiving clopidogrel, it is
critical to emphasize that high baseline platelet
reactivity (in patients receiving no antiplatelet ther-
apy) is very strongly correlated with subsequent
platelet reactivity after the initiation of clopidogrel
therapy (39,40). Therefore, HPR is a reliable mea-
sure for determining those patients with high in-
trinsic platelet reactivity during the preceding years
of plaque development, when they are not receiving
clopidogrel.
Vascular calciﬁcation and platelet reactivity. It has
been established that calcification of the coronary
arteries accurately identifies coronary atherosclerosis
(41). However, the relationship between vascular
calcification and atherosclerosis is complex; Burke
et al. (31,42) identified that vascular calcification is
least in eroded plaques, greatest in acute and healed
plaque ruptures, and intermediate in stable plaques.
Furthermore, at the cellular level, multiple cell types
are potentially implicated in the process of vascular
ossification (43,44). Again, increased vascular cal-
cification may be either a cause or an effect of HPR.Table 5. Multivariate
Respective Predictors
IVUS Variable and
Independent Pr
Lesion length/mm
HPR
Maximal calcium/°
HPR
Calcium length/mm
HPR
EEM volume/mm3
HPR
Male
Luminal volume/mm3
HPR
Male
Plaque and media volu
HPR
Male
Candidate predictors incluTable 6. Mean Values
to Platelet Reactivity
Chronic Renal Failure
Lesion length (mm)
Maximal calcium arc (°
Calcium length (mm)
EEM volume (mm3)
Luminal volume (mm3
Plaque and media volu
Values are mean  SD.Thus, more extensive, calcific plaque may lead to
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547platelet activation, or increased platelet reactivity
may augment the progression of atherosclerosis and
arterial calcification.
Study limitations. This was a single-center study.
nly patients with available pre-intervention IVUS
mages were included in the study. Platelet reactiv-
ty was assessed at only a single time point, at a
elatively late stage in the development of athero-
clerotic disease. Furthermore, it was recently
hown that platelet reactivity changes during the
rst weeks after the initiation of clopidogrel therapy
27,45). Therefore, in patients commencing this
herapy, the measurement of platelet reactivity
oon after PCI may not precisely reflect long-
erm HPR status. Only the culprit lesion and
essel were analyzed, and we did not assess more
lobal measures of atherosclerotic disease. Our
tudy demonstrates only correlative associations,
nd the possibility that platelet reactivity is caus-
tively related to atherosclerotic burden and cal-
ification, or vice versa, remains speculative. Al-
hough we attempted to account for potential
onfounding (Tables 5 and 6), we are unable to
ompletely exclude the possibility of residual
EEM Volume Adjusted
EEM Volume
Lumen Volu
p = 0.053
112
89
134
110
44
36
p = 0.028 p = 0.02
16
12
8
4
0
Lesion Length Adjusted
Lesion Length
Calcium Leng
p = 0.071
8.8
7.6
11
9.4
5.9
4.3
p = 0.058 p = 0.009616
12
8
4
0
Figure 2. Relationship Between Intravascular Ultrasound–Derive
Data represent mean values per group. Adjustments were performe
elastic membrane; HPR  high on-treatment platelet reactivity.onfounding in our results. GC O N C L U S I O N S
In a large group of patients undergoing PCI with
volumetric IVUS, we have identified that relative
resistance to the antiplatelet effects of clopidogrel as
defined by HPR status is associated with increases
in both atherosclerotic burden and plaque calcifica-
tion. Further studies are now required to precisely
define the mechanisms whereby platelets that are
relatively resistant to the effects of clopidogrel are
associated with this increase in atherosclerotic dis-
ease and if this may be a contributing factor in
adverse clinical events. The higher resolution pro-
vided by optical coherence tomography compared
with IVUS may enable the further identification
of atheromatous characteristics that are associ-
ated with high platelet reactivity. These findings
have important implications for our understand-
ing of the pathobiology and treatment of athero-
sclerotic disease.
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Adjusted
Lumen Volume
49
41
p = 0.016
Plaque & Media
Volume
Adjusted
Plaque & Media
Volume
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69
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Adjusted
Calcium Length
7.2
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